Update Your Colistin and Polymyxin B Protocols
You'll see more focus on optimizing polymyxin antibiotics...due to new guidelines from the Infectious Diseases Society of America and others.
IV colistin (polymyxin E) and polymyxin B have been around for decades. But nephrotoxicity concerns limit their use.
Now we're reaching for polymyxins more often due to increases in multidrug-resistant (MDR) gram-negative organisms, such as carbapenem-resistant Enterobacteriaceae or some Pseudomonas or Acinetobacter.
Get unlimited access through an Enterprise license
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Not sold to individuals